公开(公告)号：WO2022256298A1

公开(公告)日：2022-12-08

申请号：PCT/US2022/031548

申请日：2022-05-31

Applicant: VERGE ANALYTICS, INC.

Inventor： ROSEN, Mark D. ,  LIANG, Weiling ,  GALEMMO, JR., Robert A.

IPC: C07D487/04 ,  A61K31/519 ,  A61P25/00 ,  A61P25/02 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28

Abstract: The present invention relates to compounds of formula (I) that are inhibitors of PlKfyve kinase and are therefore useful for the treatment of e.g. neurological diseases, such as e.g. amyotrophic lateral sclerosis (ALS), Parkinson's disease, Alzheimer's disease, Huntington's disease, ADHD, schizophrenia, depression, or bipolar disorder. An exemplary compound is e.g. 4-[7-[3-(m-tolyl)pyrazol-l-yl]-2-(3- pyridyl)imidazo[l,2-a] pyrimidin-5-yl] morpholine (compound 3) Data on the PlKfyve kinase inhibition are provided:

公开(公告)号：WO2021146192A1

公开(公告)日：2021-07-22

申请号：PCT/US2021/013077

申请日：2021-01-12

Applicant: VERGE ANALYTICS, INC.

Inventor： ROSEN, Mark D. ,  GALEMMO, JR., Robert A. ,  LIANG, Weiling

IPC: A61P3/00 ,  A61P21/00 ,  A61P25/00 ,  A61P35/00 ,  C07D471/04 ,  A61K31/4162 ,  C07D487/04

Abstract: The present disclosure provides compounds that are inhibitors of PIKfyve kinases useful for the treatment of neurological diseases treatable by inhibition of PIKfyve. Also provided are pharmaceutical compositions containing such compounds, and methods of treatment using such compounds.

公开(公告)号：WO2021113633A1

公开(公告)日：2021-06-10

申请号：PCT/US2020/063298

申请日：2020-12-04

Applicant: VERGE ANALYTICS, INC.

Inventor： ROSEN, Mark D. ,  GALEMMO, JR., Robert A. ,  GUILFORD, William J. ,  LIANG, Weiling

IPC: C07D491/147 ,  A61P25/00 ,  A61K31/519

Abstract: The present disclosure provides compounds that are inhibitors of PIKfyve and/or PI3 kinases, and are therefore useful for the treatment of neurological diseases that are treatable by inhibition of PIKfyve. Also provided are pharmaceutical compositions containing such compounds, and methods of treatment using such compounds.

公开(公告)号：WO2022256299A1

公开(公告)日：2022-12-08

申请号：PCT/US2022/031550

申请日：2022-05-31

Applicant: VERGE ANALYTICS, INC.

Inventor： ROSEN, Mark D. ,  LIANG, Weiling ,  GALEMMO, JR., Robert A.

IPC: C07D491/04 ,  A61K31/4355 ,  A61P25/00 ,  A61P25/02 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28

Abstract: The present invention relates to compounds of formula (I) that are inhibitors of PlKfyve kinase and are therefore useful for the treatment of e.g. neurological diseases, such as e.g. amyotrophic lateral sclerosis (ALS), Parkinson's disease, Alzheimer's disease, Huntington's disease, ADHD, schizophrenia, depression, or bipolar disorder. An exemplary compound is e.g. 7-morpholino-5-(3-phenyl-lH- pyrazol-l-yl)-2-(lH-pyrazol-4-yl)furo[3, 2-b]pyridine (compound 10) Data on the PlKfyve kinase inhibition are provided, e.g.:

公开(公告)号：WO2022256297A1

公开(公告)日：2022-12-08

申请号：PCT/US2022/031546

申请日：2022-05-31

Applicant: VERGE ANALYTICS, INC.

Inventor： ROSEN, Mark D. ,  LIANG, Weiling ,  GALEMMO, JR., Robert A.

IPC: C07D487/04 ,  A61K31/519 ,  A61P25/00 ,  A61P25/02 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28

Abstract: The present invention relates to compounds of formula (I) that are inhibitors of PlKfyve kinase and are therefore useful for the treatment of e.g. neurological diseases, such as e.g. amyotrophic lateral sclerosis (ALS), Parkinson's disease, Alzheimer's disease, Huntington's disease, ADHD, schizophrenia, depression, or bipolar disorder. An exemplary compound is e.g. 4-(6-(1-methyl-1H-pyrazol-3-yl)-2-(3- (m-tolyl)-1H-pyrazol-1-yl)-5H-pyrrolo[3,2-d]pyrimidin-4-yl)morpholine hydrochloride (compound 7) Data on the PlKfyve kinase inhibition are provided.